A secretory GAA polypeptide and its application

By optimizing the delivery of secretory signal peptides via GAA variants and recombinant AAV vectors, the problems of enzyme activity deficiency and uneven tissue distribution in the treatment of Pompe disease have been solved, achieving efficient and safe gene therapy and reducing treatment costs.

CN123106917APending Publication Date: 2026-11-17BEIJING GENECRADLE PHARM CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202510617152.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing gene therapy methods for treating Pompe disease have problems such as enzyme deficiency, uneven tissue distribution, high safety risks, and high treatment costs. The secretion efficiency and tissue distribution of existing secretory GAA variants are still not entirely satisfactory.

Method used

By truncating wild-type GAA protein and optimizing the secretion signal peptide, a secretory GAA variant with a unique sequence was obtained, which improved the expression level and stability of the protein. The variant was then delivered to the target tissue using a recombinant AAV vector, achieving efficient secretion and tissue uptake.

Benefits of technology

It significantly enhanced the extracellular secretion capacity and total amount of GAA, increased the distribution of the enzyme in diseased tissues, effectively decomposed accumulated glycogen, alleviated pathological symptoms, and reduced the treatment burden and cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005401391070000241
    Figure BDA0005401391070000241
  • Figure BDA0005401391070000242
    Figure BDA0005401391070000242
  • Figure BDA0005401391070000243
    Figure BDA0005401391070000243
Patent Text Reader

Abstract

This invention relates to secretory GAA polypeptides for gene therapy of glycogen storage diseases (especially Pompe disease), polynucleotides encoding said secretory GAA polypeptides and expression constructs, recombinant viral vectors containing said constructs, pharmaceutical compositions and their therapeutic applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to gene therapy, and more particularly to secretory GAA polypeptides for gene therapy of glycogen storage diseases (especially Pompe disease), polynucleotides encoding said secretory GAA polypeptides and expression constructs, recombinant viral vectors comprising said constructs, pharmaceutical compositions and their therapeutic applications. Background Technology

[0002] Acidic α-glucosidase (GAA), also known as lysosomal α-glucosidase, is an exo-1,4-α-D-glucosidase essential for glycogen degradation in lysosomes. It hydrolyzes α-1,4 and α-1,6 glycosidic bonds to release terminal α-D-glucose. Unlike secretory proteins with secretory signal peptides, native GAA, as a lysosomal protein, has low self-secretion efficiency. After synthesis in the endoplasmic reticulum, it is primarily transported to lysosomes via various transport pathways, where it functions to degrade glycogen and release glucose.

[0003] Pompe disease is a rare, inherited autosomal recessive lysosomal storage disorder caused by mutations in the GAA gene, which encodes acid alpha-glucosidase. The key pathological mechanism lies in the deficiency of GAA enzyme activity, leading to uncontrolled accumulation of glycogen in lysosomes and resulting in functional impairment of skeletal muscle, cardiac muscle, and other tissues and organs. Depending on the time of onset and severity, Pompe disease can be classified into infancy, childhood, and adulthood, manifesting as progressive motor dysfunction, respiratory failure, and myocardial hypertrophy. Without treatment, this disease, especially the infantile form, can lead to early death.

[0004] Enzyme replacement therapy (ERT) is currently the main treatment for Pompe disease. Its core principle is to supplement patients with exogenous GAA enzymes to help break down glycogen and reduce its excessive accumulation in lysosomes. ERT has improved patient survival and partially restored muscle function. However, existing treatments still have many limitations. For example, their effectiveness is limited in some affected tissues, including skeletal muscle and the central nervous system, and they often require long-term, frequent drug infusions, increasing the treatment burden and cost, and significantly impacting patients' quality of life.

[0005] Gene therapy, as a potential treatment for Pompe disease, aims to address the pathological mechanisms of the disease by restoring enzyme activity through the introduction of a functional acid α-glucosidase (GAA) gene. It has been previously demonstrated that intravenous injection of an adenovirus vector encoding GAA can achieve systemic correction of glycogen storage in a Pompe disease GAA knockout (GAA-KO) mouse model; however, further studies have shown that glycogen gradually re-accumulates within months after vector administration (Ding, EY, et al. (2001) Hum. Gene Ther. 12:955–965). Furthermore, in gene therapy, studies have shown that high doses of viral vectors are often required to achieve sufficient therapeutic effects. This increases the cost of gene therapy, limiting its practical clinical accessibility; it may also lead to off-target effects or non-specific toxicity, increasing safety risks.

[0006] To improve the efficiency of gene therapy, existing literature reports the use of truncated GAA forms combined with secretory signal peptides to enhance extracellular GAA secretion and to cross-correct pathological glycogen accumulation in various tissues and cells through uptake of secretory GAAs by animal tissues. However, the reported secretory efficacy and tissue distribution of secretory GAA forms are still not entirely satisfactory. See WO2004064750 and CN110050063A.

[0007] Therefore, new treatment methods are still needed in this field to further improve the treatment of patients with Pompe disease. Invention Overview

[0009] Through dedicated research, the inventors explored the application of secretory GAA variants in the treatment of Pompe disease. Specifically, they obtained GAA variants with improved secretion by truncating wild-type GAA protein and modifying the GAA protein secretion signal peptide. The GAA variants of this invention possess unique variant sequences, improving protein expression levels and stability compared to prior art reported secretory GAA variants. In vitro and animal experiments showed that the GAA variants obtained by this invention significantly enhanced extracellular GAA secretion compared to wild-type GAA, and significantly increased the total amount of GAA compared to prior art secretory GAA variants.

[0010] In a first aspect, the present invention provides a secretory acidic α-glucosidase (GAA) polypeptide. In some embodiments, the secretory GAA polypeptide according to the invention comprises or consists of a truncated GAA polypeptide with a heterologous secretory signal peptide fused to its N-terminus, wherein the heterologous secretory signal peptide comprises or consists of an amino acid sequence selected from SEQ ID NOs:2-8, particularly the amino acid sequence of SEQ ID NOs:2, 5, or 7, wherein the truncated GAA polypeptide is truncated by 35 to 70 consecutive amino acids, for example, 35 or 70 consecutive amino acids, at the N-terminus relative to a full-length GAA. In some embodiments, the truncated GAA polypeptide is truncated by 35 consecutive amino acids at the N-terminus relative to a full-length GAA. In other embodiments, the full-length GAA polypeptide is a human full-length GAA polypeptide or a full-length GAA polypeptide derived from mammals (e.g., non-human primates). In some embodiments, the full-length GAA polypeptide comprises, or is composed of, the amino acid sequence of SEQ ID NO:1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with it. In some embodiments, the truncated GAA polypeptide comprises or is composed of, the amino acid sequence shown in SEQ ID NO:41 or SEQ ID NO:42 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with it. In some embodiments, the N-terminus of the heterologous signal peptide may or may not contain a methionine residue.

[0011] In a second aspect, the present invention provides a polynucleotide encoding a secretory GAA polypeptide of the first aspect of the invention. In some embodiments, the heterologous signal peptide is encoded by a nucleotide sequence selected from SEQ ID NOs:12-18, particularly a nucleotide sequence of SEQ ID NO:12, 15, or 17.

[0012] In a third aspect, the present invention provides an expression construct comprising a polynucleotide of the second aspect of the present invention. In some embodiments, the expression construct comprises the following elements functionally linked to each other in the transcriptional direction: a promoter, and a polynucleotide encoding a secretory GAA polypeptide according to the second aspect of the present invention. In some embodiments, the promoter is selected from constitutive promoters and tissue-specific promoters, particularly constitutive promoters selected from: CAG promoter, CAR promoter, PGK promoter, SV40 early promoter, human elongation factor 1α subunit (EF1α) promoter, cytomegalovirus (CMV) early gene promoter, chicken β-actin (CBA) promoter, β-glucuronidase (GUSB) promoter, or ubiquitin C (UBC) promoter. In still other embodiments, the promoter is the CAR promoter shown in SEQ ID NO:10. In yet other embodiments, the expression construct according to the invention comprises the following elements functionally linked to each other in the transcriptional direction: - a promoter, - optionally, a Kozak sequence, - a polynucleotide encoding secretory GAA, and - a transcription terminator, such as a polyA sequence selected from the late polyA sequence of SV40, the polyA sequence of rabbit β-globin, and the polyA sequence of bovine growth hormone.

[0013] In a fourth aspect, the present invention provides a vector comprising an expression construct according to the third aspect of the invention, optionally wherein the vector is a plasmid or viral vector, such as a recombinant lentiviral vector, a recombinant AAV viral vector, or a baculovirus vector. In some embodiments, the present invention provides a recombinant adeno-associated virus (AAV) vector, wherein the recombinant AAV vector comprises in its genome: a. 5' and 3' AAV inverted terminal repeat (ITR) sequences, and b. an expression construct according to the third aspect of the invention located between the 5' and 3' ITRs. In some embodiments of the recombinant AAV viral vector according to the present invention, the recombinant AAV viral vector of the present invention comprises a polynucleotide encoding a truncated GAA, said polynucleotide being a human codon-optimized sequence. In some embodiments of the recombinant AAV viral vector according to the present invention, the TIR sequence is a wild-type AAV2 ITR sequence, or one of the ITRs is an AA2ΔITR sequence lacking a functional terminal unwinding site (trs) and optionally a D sequence. In some embodiments of the recombinant AAV viral vector according to the present invention, the vector is an ssAAV vector or a scAAV vector. In some embodiments of the recombinant AAV viral vector according to the present invention, the recombinant AAV vector comprises capsid proteins from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVPHP.B and AAVPHP.eB, especially AAV9 serotype, or comprises a chimeric capsid. Preferably, the recombinant AAV vector is an AAV2 / 9 vector.

[0014] In a fifth aspect, the present invention provides host cells comprising a polynucleotide according to the second aspect of the invention or an expression construct according to the third aspect of the invention, or transformed with a vector according to the fourth aspect of the invention. In some embodiments, the host cells are hepatocytes or muscle cells.

[0015] In a sixth aspect, the present invention provides a pharmaceutical composition comprising a secretory GAA polypeptide according to a first aspect of the present invention, a polynucleotide according to a second aspect of the present invention, an expression construct according to a third aspect of the present invention, a vector according to a fourth aspect of the present invention or a cell according to a fifth aspect of the present invention, and optionally a pharmaceutically acceptable carrier.

[0016] In a seventh aspect, the present invention provides the use of a secretory GAA polypeptide according to a first aspect of the invention, a polynucleotide according to a second aspect of the invention, an expression construct according to a third aspect of the invention, a vector according to a fourth aspect of the invention, or a cell according to a fifth aspect of the invention in the preparation of a medicament, wherein the medicament is used for the prevention or treatment of acid α-glucosidase deficiency or glycogen storage disease. In some embodiments, the glycogen storage disease is selected from glycogen storage disease type II (GSD II, Pompe disease) or glycogen storage disease type III (GSD III). Attached Figure Description

[0017] Figure 1 This shows a schematic diagram of the structure of the pAAV-CAR-GAA plasmid vector.

[0018] Figure 2A and 2B The results showed that, in in vitro cell culture assays, compared with untransfected Huh-7 cells (i.e., blank control), the lysates of Huh-7 cells transfected with the basic construct MD110 or constructs MD806, 807, 808, 809, 810, 811, 812, or 813 significantly increased the yield of lysates of Huh-7 cells transfected with the basic construct MD110 or constructs MD806, 807, 808, 809, 810, 811, 812, or 813. Figure 2A ) and culture supernatant ( Figure 2B The GAA enzyme activity was measured in the sample. The bar chart shows the mean ± SD of GAA enzyme activity levels from cells and supernatants derived from three different cell transfection wells. Statistical analysis was performed using one-way ANOVA, where * indicates p < 0.05, **** indicates p < 0.0001, and ns indicates no statistical significance.

[0019] Figure 3 The display shows that, Figure 2A and Figure 2B In the in vitro cell experiments described, the total GAA enzyme activity obtained after transfection with different constructs was calculated based on the total protein content of the cell lysate and the total volume of the cell culture supernatant, using the GAA enzyme activity measured in the cell lysate and cell culture supernatant. The bar chart shows the mean ± SD of the GAA enzyme activity levels from cells and supernatants derived from three different cell transfection wells. Statistical analysis was performed using one-way ANOVA, where * indicates p < 0.05, ** indicates p < 0.01, **** indicates p < 0.0001, and ns indicates no statistical significance.

[0020] Figure 4The results show that in the in vitro AAV infection of Huh-7 cells, the total GAA enzyme activity obtained after infection with AAV9 virus containing different constructs was determined by measuring the GAA enzyme activity in the cell lysate and cell culture supernatant, based on the total protein content of the cell lysate and the total volume of the cell culture supernatant. The bar chart shows the mean ± SD of the GAA enzyme activity levels from cells and supernatants derived from three different cell transfection wells. Statistical analysis was performed using one-way ANOVA, where * indicates p < 0.05, ** indicates p < 0.01, and ns indicates no statistical significance.

[0021] Figure 5 This study showed the GAA enzyme activity in the heart and liver tissues of wild-type C57 mice, measured 4 weeks after IV injection of AAV9 virus containing different constructs, compared to the control group (receiving IV injection of PBS). The bar chart shows the mean ± SD of GAA enzyme activity levels derived from three different mice. Statistical analysis was performed using a two-way ANOVA, where ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001, and ns indicates no statistical significance.

[0022] Figure 6 This study showed the GAA enzyme activity in the blood of wild-type C57 mice 4 weeks after IV injection of AAV9 virus containing different constructs, compared to the control group (which received IV injection of PBS). The bar chart shows the mean ± SE of GAA enzyme activity levels derived from three different mice. Statistical analysis was performed using one-way ANOVA, where * indicates p < 0.05, ** indicates p < 0.01, **** indicates p < 0.0001, and ns indicates no statistical significance. Summary of the Invention

[0023] Secretion signal peptides are short amino acid sequences that attach to the N-terminus of nascent polypeptide chains during the early stages of protein synthesis. They guide newly synthesized proteins across the endoplasmic reticulum membrane and into the endoplasmic reticulum. Subsequently, these proteins are processed in the endoplasmic reticulum and Golgi apparatus and are eventually secreted extracellularly.

[0024] Acid α-glucosidase is an enzyme that functions in lysosomes, primarily responsible for breaking down glycogen into glucose to maintain cellular energy balance. While GAA proteins possess some autocrine capacity in their natural state, their efficiency is low. Through in-depth research, the inventors have developed a secretory GAA variant with a unique sequence and its application in gene therapy for Pompe disease. The inventors discovered that the GAA variant of this invention, constructed by adding or optimizing a secretion signal peptide to a truncated GAA protein, can significantly increase the protein's ability to be secreted extracellularly. Since the modified secretory GAA protein can be efficiently taken up by other tissue cells via the mannose-6-phosphate receptor, thereby reducing the glycogen content in the taking-up cells, this means that with increased secretion, the modified GAA protein is more likely to reach diseased tissues and more effectively diffuse across multiple target tissues, exerting its intended enzymatic activity, breaking down accumulated glycogen, and alleviating pathological symptoms. This is particularly advantageous for treating diseases like Pompe disease that require significant enzyme replenishment.

[0025] Based on the above findings, this disclosure provides secretory GAA variants and gene therapy constructs, pharmaceutical compositions, and methods for treating glycogen storage diseases (especially Pompe disease) or acid glucosidase deficiency, particularly the construction, preparation, and application of recombinant AAV vectors for delivering secretory GAA variants according to the present invention.

[0026] Unless otherwise defined below, all technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. Furthermore, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting. Other features, objects, and advantages of the invention will become apparent from this specification and the accompanying drawings, and from the appended claims.

[0027] definition

[0028] The term "about" when used in conjunction with a numeric value means to cover a range of numeric values ​​having a lower limit of 5% less than the specified numeric value and an upper limit of 5% greater than the specified numeric value. The term is also intended to cover values ​​within ±1%, ±0.5%, or ±0.1% of the specified numeric value.

[0029] In this document, the terms “comprising” or “including” mean that the stated elements, integers or steps are included, but do not exclude any other elements, integers or steps.

[0030] In this document, the expression “and / or” is used to refer to any one of the listed related items, or any and all possible combinations of multiple listed related items.

[0031] The terms "acid α-glucosidase" or "acid glucosidase" or GAA are used interchangeably in this document to refer to a lysosomal enzyme that hydrolyzes α-1-4 bonds in maltose and other linear oligosaccharides, thereby degrading excess glycogen in lysosomes. When the GAA-encoding gene is expressed in a cell, the GAA polypeptide is synthesized on the endoplasmic reticulum and glycosylated during translation, with a high-mannose glycan chain attached to its N-terminus. Subsequently, in the Golgi apparatus, the high-mannose glycan chain on GAA is further modified, thereby adding mannose-6-phosphate (M6P) to GAA. Through the interaction of M6P with M6P receptors on the cell membrane, secreted GAA from outside the cell can be taken up by the cell and delivered to lysosomes, thereby performing its glycogen degradation function. The human GAA gene encodes a 3.6 kb mRNA, which, when expressed in a cell, is produced in its full-length form of 952 amino acids, including the signal peptide at positions 1-27 and the propeptide at positions 28-69. After removing the signal peptide and propeptide, the full-length GAA forms a precursor form of approximately 110 kDa (aa70-aa952), which then passes through an endosomal intermediate of approximately 90 kDa, and finally forms mature forms of approximately 76 kDa and approximately 70 kDa in lysosomes (Comparative Study EMBO J.1988Jun;7(6):1697-704.doi:10.1002 / j.1460-2075.1988.tb02998.x.Primary structure and processingof lysosomal alpha-glucosidase;homology with the intestinal sucrase-isomaltase complex). In this disclosure, unless the context clearly defines it, the term "GAA" encompasses not only the mature form of enzymatically active GAA, but also various precursor and modified forms of GAA polypeptides, including, but not limited to, the full-length form having a natural signal peptide, precursor forms with the signal peptide removed, precursor forms with the signal peptide removed and all or part of the propeptide removed, glycosylated modified forms, and phosphorylated modified forms. Furthermore, unless the context clearly defines it, the term also encompasses variants or fragments of GAA that retain glycogenolytic activity and provide at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, or approximately the same, or greater than 100% of the enzymatic activity level of full-length wild-type (natural) human GAA.

[0032] In this article, "full-length GAA" refers to a full-length GAA polypeptide carrying a natural signal peptide and a propeptide; "truncated GAA" refers to a GAA polypeptide form with a truncated amino acid sequence relative to the full-length GAA. An example of a full-length wild-type (natural) human GAA with a natural signal peptide is the full-length GAA with 952 amino acid residues under UniProtKB-P10253 in the UniPro database, and its amino acid substitution variants (e.g., allelic variants). SEQ ID NO:1 shows the amino acid sequence of this full-length human GAA under UniProtKB-P10253; SEQ ID NO:11 shows the natural signal peptide sequence corresponding to amino acid residues 1-27 of this full-length polypeptide. Human GAA has a conserved hexapeptide WIDMNE at amino acid residues 516-521, which is essential for GAA protein activity. A truncated GAA can be an N-terminal truncation, a C-terminal truncation, or both N-terminal and C-terminal truncation relative to a full-length GAA, provided that the truncated form retains glycogen hydrolytic activity and provides at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, or approximately the same, or greater than 100% of the enzyme activity level of a full-length wild-type (natural) human GAA. Full-length and truncated GAAs can have a natural amino acid sequence or be functional variants containing one or more amino acid modifications, such as amino acid insertions, deletions, and / or substitutions. For example, a full-length GAA can contain the amino acid sequence of SEQ ID NO:1 or have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or at least 99% sequence identity with it. Similarly, truncated GAA may contain the amino acid sequence of SEQ ID NO:41 or 42 or have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or at least 99% sequence identity with it. Descriptions of functional variants of GAA can be found in: UniProtKB-P10253; NP_000143.2; GenBank AAA52506.1; GenBank CAA68763.1; GenBank: EAW89583.1; GenBank ABI53718.1; and GAA polymorphisms and SNPs described in Hirschhorn, R. and Reuser, AJ (2001) The Metabolic and Molecular Basis for Inherited Disease (edited by Scriver, CR et al.), pp. 3403-3405.

[0033] In this disclosure, unless otherwise stated, references to GAA (including full-length GAA and truncated GAA) are understood to encompass human-derived GAA polypeptides, including naturally occurring variants, allelic variants, post-translational modification variants, and conformational variants, and to encompass their species homologs, including GAAs derived from any other species, including birds and mammals. In some embodiments of the invention, the GAA is preferably a human-derived polypeptide.

[0034] In this disclosure, when referring to "the truncated GAA is shortened by X consecutive amino acid residues from the N-terminus of the full-length GAA polypeptide" or similar expressions, the truncation means the deletion of amino acid residues corresponding to positions 1 through X of SEQ ID NO:1. For example, a truncation of 35 consecutive amino acid residues at the N-terminus means the deletion of residues corresponding to positions 1 through 35 of SEQ ID NO:1. Similarly, a truncation of 70 consecutive amino acid residues at the N-terminus means the deletion of residues corresponding to positions 1 through 70 of SEQ ID NO:1. The positions of the deleted residues corresponding to SEQ ID NO:1 in the truncated GAA can be readily determined by sequence alignment (e.g., using publicly available sequence alignment tools).

[0035] The term “ETR” or “enzyme replacement therapy” in this document refers to a treatment procedure for glycogen storage disorders (such as Pompe disease) or acid glucosidase deficiency, in which recombinant GAA protein is administered to a subject in need. The recombinant GAA protein used for ETR can be produced in engineered mammalian cell lines such as CHO cells, or in the milk of transgenic animals such as transgenic rabbits.

[0036] As used herein, the term "conservative" amino acid or nucleotide change refers to a neutral or near-neutral amino acid or nucleotide change that results in the protein or nucleic acid molecule containing the said amino acid or nucleotide change substantially retaining its original function. For example, a conserved amino acid substitution is the replacement or substitution of an amino acid with a different amino acid whose side chain has similar biochemical properties (e.g., charge, hydrophobicity, and size). Variations of such conserved modifications are additional to, and not exclusive to, polymorphic variants, interspecies homologs, and alleles. The following eight groups contain conserved amino acids: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine ​​(C), methionine (M) (see, for example, Creighton, Proteins (1984)). Those skilled in the art can readily detect the conservation of amino acid or nucleotide changes in a specific polypeptide or nucleotide sequence using conventional techniques, such as functional assays.

[0037] The term "functional connectivity," also known as "effective connectivity," refers to a relationship in which the specified components are in a way that allows them to function in the intended manner.

[0038] The term "sequence identity" is used to describe the sequence structural similarity between two amino acid sequences or polynucleotide sequences. To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, the sequences can be aligned for optimal comparison purposes (e.g., vacancies can be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal alignment, or non-homologous sequences can be discarded for comparison purposes). In a preferred embodiment, for comparison purposes, the length of the reference sequence being aligned is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the reference sequence length. The amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, the molecules are identical at that position.

[0039] Mathematical algorithms can be used to compare sequences and calculate the percentage of identity between two sequences. In a preferred embodiment, the Needlema and Wunsch ((1970) J. Mol. Biol. 48: 444-453) algorithm (available at http: / / www.gcg.com) is used in the GAP program integrated into the GCG software package, employing a Blossum 62 matrix or a PAM250 matrix and vacancy weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6, to determine the percentage of identity between two amino acid sequences. In yet another preferred embodiment, the GAP program in the GCG software package (available at http: / / www.gcg.com) is used, employing an NWSgapdna.CMP matrix and vacancy weights of 40, 50, 60, 70, or 80, and length weights of 1, 2, 3, 4, 5, or 6, to determine the percentage of identity between two nucleotide sequences. The particularly preferred set of parameters (and unless otherwise specified, a set of parameters to be used) is a Blossum 62 scoring matrix with a vacancy penalty of 12, a vacancy extension penalty of 4, and a shift vacancy penalty of 5.

[0040] Alternatively, the PAM120 weighted remainder table, gap length penalty of 12, and gap penalty of 4 can be used to determine the percentage of identity between two amino acid sequences or nucleotide sequences using the E. Meyers and W. Miller algorithm ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0).

[0041] The term "host cell" refers to a cell into which exogenous polynucleotides have been introduced, including progeny cells of this type. In some embodiments, the host cell can be any type of cell system that can be used to produce the recombinant AAV vector of the present invention, such as mammalian cells (e.g., HEK 293 cells suitable for producing recombinant AAV via a three-plasmid packaging system) and insect cells (e.g., sf9 cells suitable for producing recombinant AAV via a baculovirus packaging system). In other embodiments, the host cell is a mammalian cell transformed using the recombinant AAV vector of the present invention, such as hepatocytes and myocytes. The host cell can be in vivo, ex vivo, or in vitro.

[0042] The term "regulatory sequence" or "expression control sequence" refers to a nucleic acid sequence that induces, inhibits, or otherwise controls the transcription of a protein encoding a nucleic acid sequence that is effectively linked to it. Regulatory sequences can be, for example, transcription initiation sequences, enhancer sequences, intron sequences, and promoter sequences.

[0043] The terms "exogenous" and "heterogeneous" used to describe nucleic acids or peptides are used interchangeably, referring to a nucleic acid or peptide linked to a nucleic acid or peptide that is not naturally associated with it; or, the nucleic acid or peptide not naturally present at its current chromosomal or host cell location. Exogenous nucleic acid sequences also refer to sequences derived from and inserted into the same host cell or subject but existing in a non-natural state, for example, sequences existing at different copy numbers or under the control of different regulatory elements.

[0044] In this document, "isolated" polynucleotides (e.g., isolated DNA or isolated RNA) refer to polynucleotides that are at least partially isolated from at least some other components of the natural organism or virus containing them. In some embodiments, the "isolated" polynucleotides are enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more relative to the starting material. In some embodiments, the polynucleotide encoding the secretory GAA polypeptide of the present invention is isolated.

[0045] In this document, "isolated" polypeptide means a polypeptide that is at least partially isolated from at least some other components of the natural organism or virus containing it. In some embodiments, the "isolated" polypeptide is enriched at least about 10, 100, 1000, 10,000 or more relative to the starting material. In some embodiments, the secretory GAA polypeptide of the present invention is isolated.

[0046] In this document, "isolation" or "purification" of a viral vector means that the viral vector is partially isolated from at least some components of the starting material containing it. In some embodiments, the "isolated" viral vector is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more relative to the starting material. In some embodiments, the viral vector containing a polynucleotide encoding the secretory GAA polypeptide of the present invention, such as an AAV viral vector, is isolated.

[0047] In this document, the terms "viral vector" and "viral particle" are used interchangeably, referring to a viral particle (e.g., an AAV viral particle) capable of serving as a delivery vehicle for a target nucleic acid. Typically, a viral vector comprises a capsid and a viral genome (e.g., viral DNA) packaged therein, with the target nucleic acid to be delivered inserted into the viral genome. Accordingly, the recombinant viral genome packaged in the viral vector is also referred to herein as a "vector genome (vg)". In the case of a recombinant AAV viral vector, to generate recombinant viral particles capable of delivering the target nucleic acid to tissues or cells, typically only the inverted terminal repeat (ITR) cis-form element needs to be retained in the genome, while the remaining sequences required for viral packaging can be provided trans-form. Therefore, in some embodiments, the recombinant AAV viral vector of the present invention comprises a capsid and a recombinant viral genome packaged therein, wherein the recombinant viral genome comprises or consists of one or more exogenous nucleotide sequences located between two AAV ITR sequences. The two ITR sequences located at the 5' and 3' ends of the recombinant viral genome (i.e., the 5' ITR and the 3' ITR) may be identical or different.

[0048] The term "inverted terminal repeat" (ITR) in this paper refers to cis-acting elements from the AAV viral genome that play a crucial role in AAV integration, rescue, replication, and genome packaging. Natural AAV viral ITR sequences contain Rep protein binding sites (RBS) and terminal resolution sites (trs), which can be recognized by Rep protein binding and create cleavage at the trs. Natural ITR sequences can form a unique "T"-shaped secondary structure, playing a vital role in the AAV viral life cycle. The earliest isolated AAV virus, AAV2, possesses a 145 bp palindromic hairpin-structured inverted terminal repeat (ITR) located at both ends of the genome. Subsequently, different ITR sequences have been found in various serotypes of AAV viruses, but all can form hairpin structures and possess Rep binding sites. Traditional recombinant AAV viral vectors based on these wild-type ITR sequences are generally single-stranded AAV vectors (ssAAV), with the viral genome packaged in a single-stranded form within the AAV capsid. Unlike ssAAV, it has been found that by modifying the ITR and deleting the trs sequence and optionally the D sequence from one side of the ITR sequence of the AAV virus, the genome carried by the packaged recombinant AAV viral vector can become self-complementary, forming a double strand (Wang Z et al., Gene Ther. 2003; 10(26):2105-2111; McCarty DM et al., Gene Ther. 2003; 10(26):2112-2118). The AAV virus packaged in this way is also called scAAV (self-complementary AAV) virus. The packaging capacity of scAAV viral vector is smaller, only half that of ssAAV viral vector, approximately 2.2kb-2.5kb, but its transduction efficiency after infecting cells is higher.

[0049] In this document, the term ITR in relation to AAV encompasses both wild-type ITR and variant ITR. Wild-type ITRs can originate from any natural AAV virus, such as AAV2. Wild-type ITRs contain a Rep protein binding site and a terminal unwinding site (trs), enabling them to be recognized by Rep protein binding and creating a cleavage at the trs. Wild-type ITR sequences can form a distinctive "T"-shaped secondary structure. Variant ITRs are non-natural ITR sequences that can, for example, originate from any wild-type AAV ITR sequence and contain one or more nucleotide deletions, substitutions, and / or additions, and / or truncations relative to the wild-type ITR, but remain functional, i.e., capable of generating ssAAV or scAAV viral vectors. In some embodiments, a variant ITR is an AAV ITR sequence lacking the functional trs site and optionally the D region sequence (also referred to herein as a ΔITR). In some embodiments, wild-type ITRs are combined with ΔITRs to generate self-complementary recombinant AAV viral vectors (scAAV). In other implementations, two wild-type ITRs are combined to generate a single-stranded recombinant AAV viral vector (ssAAV).

[0050] In this paper, the term “capsid protein” in the context of AAV refers to the capsid proteins VP1, VP2, and VP3 of the AAV virus, which interact to form the capsid that packages the AAV viral genome. AAV viruses with capsids of different serotypes exhibit different tissue tropisms. Therefore, exogenous genes can be delivered to specific organs and tissues by selecting the source serotype of the recombinant AAV viral vector capsid (Wu Z et al., Mol Ther. 2006; 14(3):316-327).

[0051] In this document, recombinant adeno-associated viruses (AAVs) can be represented by the AAV serotype from which the capsid originates, or by the AAV serotype from which both the capsid and the genomic ITR sequence originate. In the latter case, the identifier " / " is used as a separator, with the serotype from which the capsid originates following the " / " and the serotype from which the ITR originates preceding the " / ". Thus, for example, the number 9 in the description of recombinant AAV9 indicates that the recombinant AAV has a capsid from the AAV9 serotype; while in the description of recombinant AAV2 / 9, the number before the identifier " / " indicates that the recombinant AAV has a wild-type or variant ITR sequence from AAV2, and the number after the identifier " / " indicates that the recombinant AAV has a capsid protein from AAV9.

[0052] The term "treatment" refers to a clinical intervention intended to alter the natural course of a disease in an individual receiving treatment. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or mitigating the disease state, and alleviating or improving prognosis. In some embodiments, the recombinant AAV virus of the present invention, after administration to subjects with glycogen storage disease (e.g., Pompe disease) or GAA deficiency, preferably after systemic administration, increases the level of GAA enzyme activity in multiple affected tissues (e.g., liver, skeletal muscle, myocardium, diaphragm, and / or central nervous system) of the subject. In some embodiments, the recombinant AAV virus of the present invention, after administration to subjects with glycogen storage disease (e.g., Pompe disease) or GAA deficiency, preferably after systemic administration, increases the level of GAA enzyme activity in the subject's blood. In some embodiments, the recombinant AAV virus of the present invention, after administration to subjects with glycogen storage disorders (e.g., Pompe disease) or GAA deficiency, preferably after systemic administration, reduces lysosomal glycogen storage in multiple affected tissues of the subject (especially the liver, skeletal muscle, myocardium, diaphragm, and central nervous system). In some embodiments, the recombinant AAV virus of the present invention, after administration to subjects with Pompe disease or GAA deficiency, preferably after systemic administration, improves central nervous system damage in the subject. In some embodiments, the recombinant AAV virus of the present invention, after administration to subjects with Pompe disease or GAA deficiency, preferably after systemic administration, improves skeletal muscle and myocardial damage in the subject.

[0053] In this document, "prevention" includes the suppression of the occurrence or development of a disease or symptoms of a specific disease. In some embodiments, subjects with a predisposition to Pompe disease are candidates for preventative programs. Generally, the term "prevention" refers to a hospital intervention implemented before the onset of at least one symptom of a disease. Thus, in one embodiment, prevention includes the administration of the gene therapy drug of the present invention to subjects with a GAA gene deficiency before the onset of symptoms of Pompe disease, in order to delay disease progression or prevent the onset of the disease.

[0054] Secretory GAA peptide

[0055] In a first aspect, this disclosure provides a secretory GAA polypeptide. The secretory GAA polypeptide according to the invention comprises a heterologous secretory signal peptide fused to the N-terminus of a truncated GAA. The secretory signal peptide according to the invention is selected from the secretory signal peptides shown in SEQ ID NO: 2 to 8 and their functional derivatives. The inventors have surprisingly discovered that fusing a truncated GAA polypeptide to the secretory signal peptide can significantly increase the extracellular secretion of GAA compared to wild-type GAA. Therefore, the secretory GAA polypeptide of the invention is a chimeric GAA polypeptide comprising a heterologous secretory signal peptide moiety and a truncated GAA polypeptide moiety functionally fused thereto. In some embodiments, the secretory signal peptide is the signal peptide shown in SEQ ID NO: 2 or its functional derivative. In some embodiments, the secretory signal peptide is the signal peptide shown in SEQ ID NO: 5 or its functional derivative. In another embodiment, the secretory signal peptide is the signal peptide shown in SEQ ID NO: 7 or its functional derivative. In some embodiments, a “functional derivative” of a secretory signal peptide refers to a derivative that, compared to the sequence of the signal peptide, contains one to three, particularly one to two, more particularly one amino acid deletion, insertion, addition, or substitution, and still performs the same secretory function. An example of a functional derivative of a secretory signal peptide is a functional form having or lacking a methionine residue at the N-terminus of the secretory signal peptide. The secretory function of the functional derivative can be determined in in vitro cell-based assays, as shown in Example 3, by detecting the levels of GAA protein or GAA enzyme activity in cell culture supernatant, intracellularly, or both, induced by the functional derivative fused with a truncated GAA, and comparing them with the parental secretory signal peptide. Methods for detecting protein levels are known in the art, including but not limited to Western blotting. Methods for detecting GAA enzyme activity are known in the art, including but not limited to enzymatic assays using the artificial fluorescent substrate 4-MUG (4-methylumbelliferone-α-D-glucopyranoside) or glycogen substrates.

[0056] In some embodiments, the secretory signal peptide of the present invention is functionally fused to form a truncated GAA polypeptide. In some embodiments, the truncated GAA polypeptide is shortened (i.e., deleted) by 35 to 70 consecutive amino acids from its N-terminus compared to a full-length GAA polypeptide (e.g., SEQ ID NO:1). In some embodiments, the truncated GAA polypeptide is shortened by 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 consecutive amino acids from its N-terminus compared to a full-length GAA polypeptide (e.g., SEQ ID NO:1). In some preferred embodiments, the truncated GAA polypeptide is shortened by 35 consecutive amino acids from its N-terminus compared to the full-length GAA polypeptide (e.g., SEQ ID NO: 1) (i.e., amino acid residues corresponding to positions 1-35 of SEQ ID NO: 1 are deleted). In other preferred embodiments, the truncated GAA polypeptide is shortened by 70 consecutive amino acids from its N-terminus compared to the full-length GAA polypeptide (e.g., SEQ ID NO: 1) (i.e., amino acid residues corresponding to positions 1-70 of SEQ ID NO: 1).

[0057] In one embodiment of the invention, the full-length GAA polypeptide comprises the amino acid sequence of SEQ ID NO:1, or an amino acid sequence having at least 90%, or at least 95%, 96%, 97%, 98%, 99%, or higher identity therewith. In one embodiment of the invention, the truncated GAA polypeptide is shortened from the N-terminus of the full-length GAA polypeptide by 35 to 70 consecutive amino acids. In one embodiment of the invention, the truncated GAA polypeptide comprises the amino acid sequence of SEQ ID NO:41 or 42, or an amino acid sequence having at least 90%, or at least 95%, 96%, 97%, 98%, 99%, or higher identity therewith. In some embodiments, the truncated GAA polypeptide has the sequence shown in SEQ ID NO:41 or SEQ ID NO:42, or contains 1 to 5, particularly 1 to 4, particularly 1 to 3, more particularly 1 to 2, particularly 1 amino acid substitution, such as a conserved substitution, compared to said sequence.

[0058] The secreted GAA of this invention exhibits significantly improved secretory function compared to wild-type GAA. The amount and / or activity of GAA secreted from cells can be routinely determined using methods known in the art and described in the examples. As an example, the secreted protein can be detected by directly measuring the protein itself in cell culture medium, serum, milk, etc. (e.g., by Western blotting) or by a protein activity assay (e.g., an enzymatic assay).

[0059] Polynucleotides encoding secretory GAA peptides

[0060] In a second aspect, this disclosure provides a polynucleotide encoding the secretory GAA polypeptide of the present invention. The polynucleotide may be a single-stranded or double-stranded DNA or RNA molecule, particularly DNA.

[0061] In some embodiments of the invention, the polynucleotide comprises a nucleotide sequence encoding a heterologous signal peptide. The nucleotide sequence may be a naturally occurring encoding nucleotide sequence of the signal peptide or an optimized form thereof. In some embodiments, the heterologous signal peptide is encoded by a nucleotide sequence selected from SEQ ID NOs:12-18, particularly SEQ ID NOs:12, 15, or 17.

[0062] In some embodiments of the invention, the polynucleotide comprises a nucleotide sequence encoding a truncated GAA. The nucleotide sequence may be the naturally encoded nucleotide sequence of the GAA polypeptide or a sequence-optimized form thereof. Sequence optimization aims to improve / optimize the expression of the nucleotide sequence in vivo, and may include, but is not limited to, codon optimization, alteration of GC content, reduction of the number of CpG islands, reduction of the number of optional open reading frames (ARFs), and reduction of the number of splice donor and splice acceptor sites. In some embodiments of the invention, the nucleotide sequence encoding the truncated GAA polypeptide is the naturally encoded nucleotide sequence of the GAA. In other embodiments of the invention, the polynucleotide sequence encoding a secretory GAA polypeptide is codon-optimized (i.e., codon-optimized for expression in human cells) to, for example, enhance the expression and / or stability of the polynucleotide in vivo.

[0063] Those skilled in the art can readily determine the efficacy of the polynucleotide expression of the secretory GAA polypeptide of the present invention. Such assays include, but are not limited to, cell-based in vitro assays and animal-based in vivo assays. For example, in a cell-based in vitro assay, the polynucleotide of the present invention can be inserted into a vector, such as a plasmid vector or a viral vector, and said vector can be used to transfect or transduce host cells, such as 293T or HeLa cells, or other cells, such as Huh7, and the amount and / or activity of GAA can be measured, including, for example, the amount and / or activity of GAA in cell culture supernatant, cell lysate, or both. Alternatively, a suitable in vivo method includes transducing a viral vector containing the polynucleotide of the present invention (e.g., a recombinant AAV viral vector) into a mouse model of Pompe disease or other glycogen storage diseases, or into wild-type mice, and measuring the amount and / or activity of secretory GAA in mouse blood, serum, or plasma, and / or the amount and / or activity of GAA in tissues.

[0064] In some embodiments, in in vitro cell-based assays, such as the assay described in Example 3, the amount and / or activity of GAA expressed and secreted by cells containing the polynucleotide of the present invention are determined. In some embodiments, the secretory GAA protein encoded by the polynucleotide of the present invention increases the amount and / or activity of extracellular secretory GAA by at least 50%, 100%, 150%, 200%, 220%, 250%, 270%, or 300% compared to the wild-type GAA polypeptide of SEQ ID NO: 1.

[0065] In some embodiments, in in vitro cell-based assays, such as the assay described in Example 3, the amount and / or activity of total GAA expressed in cells containing the polynucleotides of the present invention is determined. In some embodiments, the secretory GAA protein encoded by the polynucleotides of the present invention increases the amount and / or activity (the sum of intracellular and extracellular GAA) of the cells by at least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, or 20% compared to the wild-type GAA polypeptide of SEQ ID NO: 1.

[0066] In some embodiments, in in vivo studies, such as the animal studies described in Example 6, the amount and / or activity of GAA in the blood and / or tissues of animals administered a viral vector containing the polynucleotide of the present invention is determined. In some embodiments, the secretory GAA protein encoded by the polynucleotide of the present invention increases the amount and / or activity of secretory GAA in the blood compared to the wild-type GAA polypeptide of SEQ ID NO: 1. In some embodiments, the increase is at least 50%, 60%, 70%, 80%, 90%, 100%, 110%, or 120%.

[0067] Expression builder

[0068] In a third aspect, this disclosure provides expression constructs comprising the polynucleotides of the second aspect of the invention. In this disclosure, the terms "expression construct" and "expression cassette" are used interchangeably, referring to a nucleic acid construct by operatively linking the polynucleotides of the invention to one or more suitable regulatory sequences or expression control sequences to facilitate, enhance, and / or strengthen their expression and secretion in suitable host cells. Such regulatory sequences or expression control sequences are known in the art and include, for example, promoters, enhancers, introns, transcription terminators, ribosome binding sites, miRNA binding sites, etc.

[0069] The promoters used to express the constructs of this invention can be constitutive promoters or tissue-specific promoters. Those skilled in the art can select a suitable promoter based on the cell or tissue type for which GAA expression is required. GAA deficiency diseases or conditions such as Pompe disease often affect multiple organs and tissues, including but not limited to peripheral organs such as skeletal muscle and cardiac muscle, and the central nervous system (including the brain and spinal cord). Given this systemic, multi-tissue involvement, the use of constitutive promoters is advantageous in some cases. Examples of such constitutive promoters include, but are not limited to, cytomegalovirus enhancer / chicken β-actin (CAG) promoters, CAR promoters, PGK promoters, SV40 early promoters, human elongation factor 1α subunit (EF1α) promoters, cytomegalovirus (CMV) early gene promoters, chicken β-actin (CBA) promoters, β-glucuronidase (GUSB) promoters, or ubiquitin C (UBC) promoters. For descriptions of these promoters, see, for example, Niwa H, et al. Gene. 1991; 108:193-200; Viral Expression Cassette Elements to Enhance Transgene Target Specificity and Expression in Gene Therapy, Discov Med. 2015 January; 19(102):49–57; CN108795946A; CN115772520A. In some embodiments, the promoter used for the expression construct of the present invention is a CAR promoter. In this disclosure, a CAR promoter refers to a promoter comprising the nucleotide sequence shown in SEQ ID NO:10 or a functional variant thereof, particularly a CAR mutant having a T-to-C or G or A mutation at position 568 relative to SEQ ID NO:10, especially a T-to-C mutation.

[0070] In other cases, tissue-specific promoters can be operatively linked to the secretory GAA encoding the present invention to achieve more specific expression in the cells or tissues where GAA expression is desired. Examples of such tissue-specific promoters include, but are not limited to, hepatocyte-specific promoters, muscle cell-specific promoters, and nerve cell-specific promoters. As demonstrated by the examples, the secretory GAA of the present invention can significantly enhance the amount of secretory GAA in the blood compared to wild-type GAA. Using a hepatocyte-specific promoter will facilitate the expression of secretory GAA from the liver and its entry into the bloodstream to achieve cross-correction across multiple organs and tissues. Furthermore, studies have shown that the liver has a unique role in inducing immune tolerance (Local control of the immune response in the liver, Immunol Rev. 2000 Apr:174:21-34. doi:10.1034 / j.1600-0528.2002.017408.x). Therefore, in some embodiments, preferably, the promoter is a hepatocyte-specific promoter. Examples of liver-specific promoters include, for example, the α-1 antitrypsin promoter, the thyroxine transporter promoter, the albumin promoter, the thyroxine-binding globulin (TBG) promoter, the LSP promoter, etc.

[0071] As those skilled in the art will understand, in addition to promoters, the expression constructs according to the present invention may optionally include other regulatory sequences that are beneficial to the expression of the target gene. A variety of regulatory sequences that can be used for gene expression in mammalian cells are known in the art.

[0072] In some embodiments, the expression construct according to the invention comprises the following elements effectively linked to each other in the transcriptional direction:

[0073] - Promoter,

[0074] - According to the second aspect of the present invention, a polynucleotide encoding secretory GAA is used.

[0075] -Optionally, a transcription terminator, such as a polyA signal sequence.

[0076] In some embodiments, the expression construct of the present invention further includes a Kozak sequence upstream of the start codon of the GAA-encoding polynucleotide to facilitate GAA translation. The Kozak sequence used in the present invention can be a common sequence defined as GCCRCC, where R is a purine (i.e., A or G), and wherein said sequence is upstream of the start codon. In a preferred embodiment, the Kozak sequence has a 5'-GCCACC-3' sequence.

[0077] In some embodiments, the expression constructs of the present invention further include regulatory sequences that can selectively inhibit or reduce the expression of secretory GAAs in unwanted cells. An example of such regulatory sequences is a miRNA binding site, including, but not limited to, nucleotide sequences capable of specifically binding to miRNAs expressed in immune cells (e.g., antigen-presenting cells, APCs, such as macrophages and dendritic cells), such as the miR-142 binding site. See, for example, Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity, JCI Insight. 2019 Jul 11; 4(13):e99052.doi:10.1172 / jci.insight.99052; and CN115772520A. Placing such miRNA binding sites within the 3' untranslated region (3'UTR) of a GAA-encoding polynucleotide will help reduce the immunogenicity of the recombinant AAV vector of the present invention.

[0078] In some embodiments, the expression construct of the present invention comprises at least one polyA tail downstream of a multinucleotide encoding a GAA and miRNA binding site. Any suitable polyA sequence may be used, including but not limited to, preferably selected from the SV40 late polyA sequence, the rabbit β-globin polyA sequence, the bovine growth hormone polyA sequence, the human growth hormone polyA sequence, or any variant thereof.

[0079] carrier

[0080] In a fourth aspect, this disclosure provides vectors comprising secretory GAA-encoding polynucleotides of the second aspect of the invention. Vectors according to the invention are suitable for the expression and secretion of secretory GAA proteins of the invention, particularly for gene therapy. Such vectors include, but are not limited to, non-viral vectors and viral vectors. In one embodiment, the vector of the invention is a non-viral vector. In some embodiments, the non-viral vector is a nucleic acid vector. In one embodiment, the nucleic acid vector is a plasmid, such as an expression plasmid, shuttle plasmid, or baculosome. In one embodiment, the nucleic acid vector is a transposon-based system, such as the Sleeping Beauty transposon system. In one embodiment, the non-viral vector is a nanoparticle comprising the polynucleotide of the invention, such as lipid nanoparticles (LNPs). In another embodiment, the vector of the invention is a viral vector. Examples of viral vectors include, but are not limited to, recombinant lentiviral vectors, recombinant AAV viral vectors, adenovirus vectors, bocavirus vectors, AAV / bocavirus hybrids, herpes simplex virus vectors, or baculovirus vectors. For viral vectors administered and delivered to subjects, these vectors are typically replication-deficient, containing a replication-deficient viral genome sequence of an expression construct according to the third aspect of the invention, packaged in a viral capsid or envelope. Such replication-deficient recombinant viral particles do not produce progeny virions but retain the ability to infect target cells. Furthermore, viral vectors with specific tissue tropism can be selected based on the cell and tissue type for which GAA is expressed, or the type and tissue of disease-affected cells targeted as needed, to enhance the targeting and / or safety of gene therapy. As an example, the viral vector can target liver tissue or cells, muscle cells, CNS cells (e.g., brain cells), hematopoietic stem cells, or any combination thereof.

[0081] Packaging cell lines for producing recombinant viral vectors (e.g., recombinant AAV vectors) can be prokaryotic or eukaryotic cells (e.g., human cells, insect cells, or yeast cells) containing exogenous DNA introduced into the cells by any means (e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, transfection, and protoplast fusion). Packaging cell lines include, but are not limited to, E. coli cells, yeast cells, human cells, non-human cells, mammalian cells, insect cells, HEK293 cells, hepatocytes, kidney cells, glial cells, or stem cells.

[0082] In some preferred embodiments, the vector of the present invention is a recombinant AAV viral vector. AAV viral vectors can efficiently introduce exogenous genes into recipient cells due to their natural properties, and the viral vectors exhibit good safety. Furthermore, there are numerous AAV viral serotypes, and different serotypes have different tissue tropisms; therefore, the use of AAV vectors can transport exogenous genes to specific organs and tissues (Wu Z et al., Mol Ther. 2006; 14(3):316-327). On the other hand, AAV vectors are chemically stable and exhibit strong resistance to acids, alkalis, and high temperatures (Gruntman AM et al., HumGene Ther Methods. 2015; 26(2):71-76), making it easy to develop highly stable biological products. In terms of preparation, existing technologies have relatively mature packaging systems for AAV vectors, facilitating large-scale production. Due to these characteristics, AAV vectors are gradually becoming a widely used tool in gene therapy.

[0083] In some embodiments, the recombinant AAV viral vector of the present invention comprises a capsid and a recombinant viral genome (i.e., vector genome) packaged within the capsid. In this disclosure, unless otherwise stated, the AAV capsid, ITR, and other AAV components mentioned herein in the description of the recombinant AAV viral vector of the present invention and in its production can be readily selected from any natural or artificial AAV, including, but not limited to, AAVs commonly identified as having serotypes AAV1, AAV2, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, or AAV12, or any combination thereof. The genomic sequences of various serotypes and artificial AAVs, along with their natural inverted terminal repeat (ITR) sequences, Rep proteins, and capsid cap proteins, are known in the art, and their sequences can be found in publicly available databases such as GenBank or in the literature.

[0084] In some embodiments, the recombinant AAV viral vector of the present invention comprises a vector genome, wherein the AAV vector genome contains an expression construct for guiding the expression of the secretory GAA polypeptide of the present invention, particularly an expression construct according to the third aspect of the present invention. As an example, the AAV vector genome comprises at least: an AAV 5'ITR or AAV 5'ΔITR in the 5' to 3' direction, an expression construct according to the third aspect of the present invention containing a polynucleotide encoding the secretory GAA of the present invention, and an AAV 3'ITR or AAV 3'ΔITR. The ITR is a genetic element responsible for genome replication and packaging during vector production and is the only viral cis-element required to produce recombinant AAV (i.e., rAAV). ITRs from different sources of AAV can be selected, and in some cases, the ITR can come from an AAV different from the capsid of the viral particle. The ΔITR is an ITR with the D sequence and terminal unwinding site trs deleted, enabling the genome carried by the packaged recombinant adeno-associated virus vector to self-complement, forming a double strand, significantly improving the in vitro and in vivo transduction efficiency of the AAV vector. Double-stranded AAV viruses, i.e., scAAV, can be packaged using a combination of ΔITR and ITR. Single-stranded AAV viruses, i.e., ssAAV, can be packaged using unmutated bilateral ITRs. In some embodiments, the recombinant AAV virus vector according to the present invention is an ssAAV vector. In other embodiments, the recombinant AAV virus vector according to the present invention is an scAAV vector. In one embodiment, both the 5' ITR and 3' ITR are ITR sequences derived from AAV2.

[0085] In some embodiments, the recombinant AAV viral vector of the present invention comprises an AAV capsid capable of transducing target cells. In some embodiments, the recombinant AAV vector comprises a capsid protein, or a variant thereof, from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVPHP.B, and AAVPHP.eB, particularly serotype AAV9. In some embodiments, the recombinant AAV vector comprises a chimeric capsid, or a variant thereof. Hereinafter, an AAV “chimeric capsid” means that the capsid comprises a VP capsid protein derived from at least two different AAV serotypes. Hereinafter, an AAV capsid “variant” means having sequence modifications relative to a known AAV capsid, including conserved amino acid substitutions, and having at least 90%, at least 95%, at least 97%, at least 99%, or greater sequence identity with the amino acid sequence of a known AAV capsid.

[0086] In some embodiments, the present invention provides a recombinant AAV viral vector comprising a capsid, wherein the capsid is composed of a capsid protein capable of crossing the blood-brain barrier, such as AAV9, AAVPHP.B, or AAVPHP.eB capsid proteins. In some embodiments, the recombinant AAV vector of the present invention transduces neurons in the central nervous system (CNS) and also transduces peripheral non-neuronal cells. In other embodiments, the recombinant AAV vector, after systemic administration, targets and transduces muscle cells and neurons. In another embodiment, the recombinant AAV vector, after systemic administration, targets and transduces peripheral organs and the central nervous system of a subject. In yet another embodiment, the recombinant AAV vector, after systemic administration, targets and transduces most tissues of a subject (e.g., brain, spinal cord, skeletal muscle, heart, and liver), and preferably, compared to control subjects who have not received recombinant AAV vector administration, the recombinant AAV vector results in higher GAA expression and / or enzyme activity in the targeted and transduced tissues.

[0087] AAV9 exhibits high tropism for muscle and can cross the blood-brain barrier, thereby enabling efficient transduction to multiple target tissues. Expression of the secretory GAA of the present invention via an AAV9 vector, as demonstrated by examples, allows for increased levels and activity of the functional GAA in circulation, which effectively enables cross-correction to surrounding untransduced cells and tissues. Therefore, without being bound by specific theories, expression of the secretory-enhanced secretory GAA peptide of the present invention using an AAV9 vector will promote efficient diffusion of the expressed protein among multiple target tissues. In some embodiments, the present invention correspondingly provides a recombinant AAV vector having a capsid derived from the AAV9 serotype (also referred to herein as an AAV9 vector); preferably, the recombinant AAV vector has a wild-type or variant ITR sequence from AAV2 in its genome (also referred to herein as an AAV2 / 9 vector).

[0088] The recombinant adeno-associated virus (AAV) vector of the present invention can be produced using known techniques. Such methods involve culturing packaging cells (including, for example, mammalian and insect cells) containing a nucleic acid sequence encoding the AAV capsid; a functional rep gene; an expression construct as described herein, flanked by an AAV inverted terminal repeat (ITR) or ΔITR; and sufficient helper functions to allow the expression construct to be packaged into the AAV capsid protein. Currently commonly used AAV vector packaging systems mainly include three-plasmid co-transfection systems, systems using adenovirus as a helper virus, packaging systems using herpes simplex virus type 1 (HSV1) as a helper virus, and baculovirus-based packaging systems. Each packaging system has its own characteristics, and those skilled in the art can make appropriate selections as needed for the production of the AAV vector according to the present invention. Furthermore, other methods of AAV production known in the art can also be utilized, for example, production via yeast.

[0089] In some embodiments, baculovirus-insect cells are used to produce the recombinant AAV virus of the present invention. As an example, in this production process, the target GAA gene is inserted into a plasmid called a donor vector. The donor target gene is then transferred from the donor plasmid to a vector called a "bacmid" (i.e., a baculovirus shuttle plasmid). This transfer can be achieved by transforming the donor plasmid into a bacterial strain (typically *E. coli*) carrying the paternal bacmid. The resulting recombinant bacmid is used to infect insect cells (e.g., sf9 or High-Five) for initial baculovirus production and assembly to obtain first-generation baculovirus (P1). Optionally, the P1 baculovirus is amplified to a suitable titer in the same or different insect cells (e.g., sf9) to obtain second-generation baculovirus (P2). Insect cell lines (e.g., sf9 or High-Five) are infected or co-infected with one or more P1 or P2 baculoviruses to deliver all the target genes necessary for recombinant AAV production, thereby packaging and producing the recombinant AAV virus.

[0090] host cells

[0091] In a fifth aspect, this disclosure provides a secretory GAA polypeptide comprising the first aspect of the invention, a polynucleotide comprising the second aspect, an expression construct comprising the third aspect, or a vector comprising the fourth aspect, or a host cell transformed therewith. In some embodiments, the host cell is a mammalian or insect cell used to produce the viral vector of the invention (e.g., the AAV recombinant viral particle of the invention). In some embodiments, the host cell is a mammalian cell transfected with the viral vector of the invention (e.g., the AAV recombinant viral particle of the invention), such as hepatocytes, muscle cells, or nerve cells. In some embodiments, the cell is an in vivo, ex vivo, or in vitro cell. In some embodiments, the cell is a somatic cell (e.g., hepatocyte) or stem cell (e.g., liver stem cell) derived from a patient to be treated, which is further transformed in vitro and then administered to the patient.

[0092] Pharmaceutical Composition

[0093] In a seventh aspect, this disclosure provides pharmaceutical compositions comprising a secretory GAA polypeptide according to the first aspect of the invention, a polynucleotide according to the second aspect, an expression construct according to the third aspect, a vector according to the fourth aspect, or a cell according to the fifth aspect, and optionally a pharmaceutically acceptable vector. In some embodiments, the invention provides pharmaceutical compositions comprising the recombinant AAV viral vector of the invention. The pharmaceutical compositions of the invention preferably comprise pharmaceutically acceptable excipients, diluents, or vectors. The pharmaceutical compositions of the invention can be formulated into any suitable dosage form.

[0094] Examples of suitable pharmaceutically acceptable excipients, diluents, or carriers for formulation are well known in the art, including, for example, phosphate-buffered saline solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions, etc. The formulation can be prepared by conventional methods and administered to the subject at an appropriate dose. Administration of a suitably formulated composition can be achieved in various ways, for example, intravenously, intraperitoneally, subcutaneously, intramuscularly, locally, or intradermally. The specific route of administration depends particularly on the type of carrier contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical field, the dose for any patient depends on many factors, including the patient's body size, body surface area, age, sex, the specific active agent to be administered, the time and route of administration, the type and stage of the drug, infection or disease, general health condition, and concomitant use of other drugs.

[0095] In some embodiments, the pharmaceutical composition of the present invention may comprise a second active agent. In some embodiments, the second active agent is a recombinant GAA protein used in enzyme replacement therapy (ERT), such as a recombinant GAA protein derived from transgenic animal milk or productive mammalian cell lines. In some embodiments, the second active agent is a bronchodilator.

[0096] In other embodiments, the pharmaceutical compositions of the present invention may contain a second active agent capable of reducing adverse reactions (e.g., drug-resistant immune responses) during drug administration. In some cases, the second active agent may be an immunosuppressant.

[0097] It should be understood that when the pharmaceutical composition of the present invention comprises more than one active agent, the more than one active agent may be formulated in the same formulation or separately formulated in different formulations for concurrent, simultaneous or sequential administration. In the latter case, the pharmaceutical composition of the present invention is a combination product comprising the different formulations.

[0098] The pharmaceutical compositions of the present invention can be administered via any suitable route, including systemic and local administration. In a preferred embodiment, the pharmaceutical compositions of the present invention are intended for systemic administration, particularly intravenous administration. Thus, in one embodiment, the present invention provides a pharmaceutical composition comprising the recombinant AAV carrier of the present invention, wherein the pharmaceutical composition is an intravenous formulation or a lyophilized stable formulation suitable for formulation into an intravenous injection. In other embodiments, the pharmaceutical compositions of the present invention are suitable for local administration, such as direct application to or near the organ or tissue to be treated in a subject.

[0099] Methods and uses

[0100] In a seventh aspect, this disclosure provides the use and methods of secretory GAAs, polynucleotides, expression constructs, vectors, and recombinant AAV viral vectors according to the first to fifth aspects of the invention in the prevention or treatment of diseases. Diseases or conditions treatable by the secretory GAAs according to the invention include glycogen storage diseases and acid α-glucosidase deficiency, which can benefit from GAA administration.

[0101] Pompe disease, also known as acid alpha-glucosidase deficiency or glycogen storage disease type II (GSD II), is a systemic lysosomal storage disorder that primarily affects muscles but also influences the central nervous system. In affected individuals, there is a deficiency of functional acid alpha-glucosidase (GAA) in lysosomes, preventing the conversion of glycogen into glucose for utilization. This leads to the accumulation of glycogen in the lysosomes of cells, particularly in peripheral organs such as skeletal muscle and cardiac muscle, and in the cells of the central nervous system (including the brain and spinal cord). Pompe disease can be diagnosed by detecting alpha-glucosidase activity through enzymatic testing. Based on age of onset and severity, Pompe disease can be classified into two types: infantile and late-onset. Infantile-onset Pompe disease (IOPD) individuals have extremely low residual GAA activity and exhibit severe symptoms such as respiratory distress, generalized muscle weakness, and cardiopulmonary failure, often with fatal consequences. Childhood-to-adult-onset Pompe disease individuals, due to higher residual GAA activity, experience slower disease progression. This milder form of Pompe disease is also known as late-onset Pompe disease (LOPD). While myocardial defects are often absent in LOPD individuals, muscle weakness can lead to severe respiratory problems and respiratory failure. As an alternative to or complement to ERT therapy, gene therapy methods providing exogenous GAA have been proposed to overcome GAA gene defects in Pompe disease patients. The use of AAV viral vectors carrying recombinant GAA genes controlled by histiotype promoters or tissue-specific promoters in the treatment of Pompe disease has been reported in preclinical and clinical trials. See, for example, Giuseppe Vita, 2019. https: / / doi.org / 10.1007 / s10072-019-03764-z ; and Molecular Therapy: Methods & Clinical Development Vol.12March 2019; https: / / doi.org / 10.1016 / j.omtm.2019.01.006 In addition, patients with other GSDs may also benefit from GAA administration. For example, it has been shown (Sun et al., (2013) Mol Genet Metab 108(2):145; WO2010 / 005565) that GAA administration reduces glycogen in primary myoblasts derived from patients with type III glycogen storage disease (GSD III).

[0102] Therefore, in some embodiments, the present invention provides a method for preventing or treating glycogen storage diseases. In some embodiments, the method includes administering to a subject in need a preventative or therapeutically effective amount of a secretory GAA polypeptide according to a first aspect of the invention, a polynucleotide encoding a secretory GAA polypeptide according to a second aspect of the invention, an expression construct according to a third aspect of the invention, a vector according to a fourth aspect of the invention, or, in particular, a recombinant AAV vector according to a fifth aspect of the invention. The glycogen storage disease can be glycogen storage disease type I (GSDI, also known as von Gierke's disease), glycogen storage disease type II (GSDII, also known as Pompe disease), glycogen storage disease type III (GSDIII, also known as Cori disease), glycogen storage disease type IV (GSDIV), glycogen storage disease type V (GSDV), glycogen storage disease type VI (GSDVI), glycogen storage disease type VII (GSDVII), glycogen storage disease type VIII (GSDVIII), or a fatal congenital glycogen storage disease of the heart. In some preferred embodiments, the glycogen storage disease is selected from GSDII and GSDIII, particularly GSDII. Unbound by any specific theory, by improving secretion efficiency, the modified GAA protein of this invention can achieve the same therapeutic effect at a lower dose compared to the wild-type GAA protein. Furthermore, since effective GAA protein delivery requires less viral vector, the GAA variant of this invention reduces the overall dose needed for treatment while also decreasing potential side effects. This not only improves treatment safety but may also reduce treatment costs.

[0103] In some embodiments, this disclosure provides a method of treating a disease using the recombinant AAV carrier of the present invention or a pharmaceutical composition comprising thereof. In some embodiments, the disease is GSDII (i.e., Pompe disease). In other embodiments, the disease is acid alpha-glucosidase deficiency. In one embodiment, the method comprises administering the recombinant AAV carrier or pharmaceutical composition of the present invention to a subject in need. The recombinant AAV carrier or pharmaceutical composition may be administered via any suitable route, including but not limited to intramuscular, subcutaneous, intraspinal, intravenous, intrathecal, intravenous, intradiaphragmatic, intrathoracic, and intraperitoneal administration. Preferably, the recombinant AAV carrier or pharmaceutical composition of the present invention is delivered to the subject via systemic administration, particularly intravenous administration. In some embodiments, the treatment is therapeutic. In other embodiments, the treatment is prophylactic. In some embodiments, the subject is a mammal, wherein the mammal is particularly a human, primate, dog, horse, or cattle, and especially a human subject.

[0104] In methods relating to treating subjects with Pompe disease, in some embodiments, the treatment includes one or more of the following: (1) preventing or delaying the onset of Pompe disease; (2) reducing the severity of Pompe disease; (3) reducing or preventing the onset and / or exacerbation of at least one symptom of Pompe disease; (4) improving Pompe disease-related neurodegeneration and / or subject behavior; and (5) prolonging the subject's survival. Subjects with Pompe disease who may receive treatment include patients with IOPD and LOPD. In some embodiments, the subject is an IOPD patient. In still other embodiments, the subject is a LOPD patient.

[0105] In some further embodiments, the present invention provides the use of the recombinant AAV vector of the present invention in the preparation of a medicament for treating subjects with Pompe disease or subjects with acid glucosidase deficiency. The treatment comprises administering any one or more recombinant AAV vectors of the present invention to the subject, preferably by systemic administration, such as intraperitoneal (ip), intramuscular (im), intraarterial, or intravenous (iv) injection, preferably intravenous injection, to the recombinant AAV vector.

[0106] In some embodiments of the treatment methods and uses of the present invention, after administration of the recombinant AAV vector of the present invention, the GAA polypeptide is expressed in the heart, liver, muscles, and central nervous system (including the brain and spinal cord) of the subject. In still other embodiments, administration of the recombinant AAV vector results in a reduction in lysosomal glycogen stores in the skeletal muscle, myocardium, diaphragm, and central nervous system of the subject, and preferably does not induce or induces low immunogenicity. In some embodiments, administration of the recombinant AAV vector of the present invention can improve cardiac, respiratory, and / or skeletal muscle function in the subject. In still other embodiments, administration of the recombinant AAV vector of the present invention can prevent or improve lesions of the central nervous system, such as the brain, spinal cord, and / or neurons, caused by glycogen storage, such as progressive neurodegeneration. In some embodiments, administration of the recombinant AAV vector of the present invention can prolong the survival of the subject.

[0107] In some embodiments of the treatment methods and uses of the present invention, the recombinant AAV viral vector of the present invention is administered in combination with another therapeutic agent or treatment procedure. The therapeutic agent or treatment procedure that can be administered in combination with the recombinant AAV vector of the present invention may be selected from immunomodulators, bronchodilators, acetylcholinesterase inhibitors, respiratory muscle strength training (RMST), enzyme replacement therapy (ERT), and / or diaphragmatic pacing therapy. Example

[0108] Example 1: Acquisition and Screening of Signal Peptides

[0109] Existing technical literature (CN110050063A, incorporated herein by reference in its entirety) compared various truncated GAA forms with multiple secretion signal peptides, concluding that truncating the N-terminus of full-length GAA (SEQ ID NO:1) by approximately 35 to 70 amino acids, when combined with secretion signal peptides such as A1AT and SP7, can effectively enhance GAA secretion levels. Among the compared truncated forms, a 70-residue truncation appears to be superior. Among the multiple secretion signal peptides compared, the A1AT signal peptide derived from human α-1-antitrypsin showed the best performance.

[0110] To explore more effective secretory GAA variants, existing technical data were consulted to obtain the secretion signal peptide A1AT sequence (SEQ ID No. 2); and highly secreted proteins in humans were screened, and their sequences were analyzed to obtain the following secretion signal peptides: A2MG (SEQ ID No. 3), ALBU (SEQ ID No. 4), APOA1 (SEQ ID No. 5), GIP (SEQ ID No. 6), SMS (SEQ ID No. 7), SP7 (SEQ ID No. 8), and SS8 (SEQ ID No. 9).

[0111] Example 2 Molecular Construction

[0112] 1. The MD110 (pAAV-CAR-GAA) plasmid stored by Beijing Jinlan Gene Technology Co., Ltd. was used as the basic construct. Figure 1 This construct carries a GAA gene expression cassette containing the wild-type GAA amino acid sequence (SEQ ID NO.1) and a constitutive CAR promoter (SEQ ID NO.10, see CN108795946A). The MD110 plasmid was digested with NotI and SbfI as a backbone fragment. Insert fragment 1 was amplified using the promoter region primer KZ-110sp-F1 and the upstream region primers (R1 primers) of each secretion signal peptide. Insert fragment 2 was amplified using the downstream region primers (F2 primers) of each secretion signal peptide and KZ-110sp-R2. Three fragments were then ligated using in-fusion recombinase (Takara) homologous recombination to obtain constructs containing different signal peptides. In the prior art patent (CN110050063A), the A1AT secretion signal peptide replaced amino acids 2–70 of GAA as shown in that patent. The secretion signal peptide fragment used in this study replaced amino acids 2–35 of GAA. The primer sequences for molecular cloning amplification are as follows (synthesized by Sangon Biotech (Shanghai) Co., Ltd.):

[0113] KZ-110sp-F1(SEQ ID NO.20):GACGCGCTATGCGGC

[0114] KZ-110sp-R2(SEQ ID NO.21):ATGGTCTGTAGCTTCCTGCA

[0115] KZ-A1ATsp-R1(SEQ ID NO.22):

[0116] CAAGCCAGCCAGCAGGAGGATGCCCCATGACACAGAGGAGGGCATGGTGGCGGTACCCT

[0117] KZ-A1ATsp-F2(SEQ ID NO.23):

[0118] CCTGCTGGCTGGCTTGTGCTGCTTGGTCCCCGTGAGCTTGGCACACCCAGGCAGG

[0119] KZ-A2MG-R1(SEQ ID NO.24):

[0120] GCAACAACAGGACCAGGGAGGGGTGCAGCAGCTTGTTCTTGCCCATGGTGGCGGTA

[0121] KZ-A2MG-F2(SEQ ID NO.25):

[0122]

[0123] KZ-ALBUsp-R1(SEQ ID NO.26):

[0124]

[0125] KZ-ALBUsp-F2(SEQ ID NO.27):

[0126]

[0127] KZ-APOA1sp-R1(SEQ ID NO.28):

[0128]

[0129] KZ-APOA1sp-F2(SEQ ID NO.29):

[0130]

[0131] KZ-GIPsp-R1(SEQ ID NO.30):

[0132]

[0133] KZ-GIPsp-F2 (SEQ ID NO.31):

[0134]

[0135] KZ-SMS-nR1 (SEQ ID NO.32):

[0136]

[0137] KZ-SMS-nF2 (SEQ ID NO.33):

[0138]

[0139] KZ-sp7-nR1 (SEQ ID NO.34):

[0140]

[0141] KZ-sp7-nF2 (SEQ ID NO.35):

[0142]

[0143] KZ-SS8sp-R1 (SEQ ID NO.36):

[0144]

[0145] KZ-SS8sp-F2 (SEQ ID NO.37):

[0146]

[0147] After ligation and transformation, clones are selected for sequencing. Clones with correct sequencing results are then added to the library, numbered as follows:

[0148] MD806: pAAV-CAR-A1ATsp-Δ70-GAA

[0149] MD807: pAAV-CAR-A2MGsp-Δ35-GAA

[0150] MD808: pAAV-CAR-ALBUsp-Δ35-GAA

[0151] MD809: pAAV-CAR-APOA1sp-Δ35-GAA

[0152] MD810: pAAV-CAR-GIPsp-Δ35-GAA

[0153] MD811: pAAV-CAR-SMSsp-Δ35-GAA

[0154] MD812: pAAV-CAR-sp7△35-GAA

[0155] MD813: pAAV-CAR-SS8-Δ35-GAA

[0156] Example 3: Comparison of intracellular and supernatant enzyme activities after transfection of cells with different constructs

[0157] The clones obtained in Example 2 were used to extract plasmids using a miniprep kit (Tiangen Biotech). Human hepatocellular carcinoma cells (Huh-7) were seeded into 24-well plates. When the cells reached approximately 80% confluence, they were transfected with the aforementioned construct. Six hours after transfection, the medium was replaced with serum-free DMEM (Thermo), and the cells were cultured for another 72 hours. The cell culture supernatant was collected, and the cells were digested and collected. Cells were lysed using a repeated freeze-thaw cycle followed by centrifugation, and total cellular protein was extracted. The total protein concentration of plasmid-transfected cells and untransfected blank cells was measured using the Pierce BCA Protein Aaasy Kit (ThermoFisher, USA). Detailed procedures were performed according to the kit instructions.

[0158] GAA protease activity was detected using cell lysate extracts and supernatants. 10 μl of each extract and supernatant were reacted with 4-MUG (4-methylumbelliferone-α-D-glucopyranoside) as a substrate under acidic conditions (pH 3.8-4.0) for 1 h, followed by fluorescence detection (excitation 365 nm, emission 450 nm). The concentration of 4-MU generated was calculated based on a standard curve, and the GAA protease activity of the sample was further calculated. GAA protease activity in cell lysates was reported in nmol / hour / mg protein; GAA protease activity in supernatants was reported in nmol / hour / mL. (See Qiu Wenjuan et al., 2010, Establishment and Clinical Application of a Platform for Assaying Acidic α-glucosidase Activity in Dried Blood Filter Paper and Leukocytes)

[0159] See results Figure 2A (cell proteins) Figure 2B (Supernatant). After modification with secretory signal peptides, the intracellular enzyme activity of each plasmid was significantly decreased compared to MD110, while the enzyme activity in the supernatant was significantly increased. Specifically, the enzyme activity in the cell culture supernatant after transfection with MD806, MD809, and MD811 was extremely significantly increased and significantly higher than other groups; no significant differences were observed among the three groups. Figure 2B Comparing the cellular protease activities of the three groups, the MD811 group was significantly higher than the MD806 and MD809 groups. Figure 2A The total enzyme activity after transfection was calculated based on the total protein content and the total volume of the supernatant. Figure 3The total enzyme activity in the MD811 group was significantly higher than that in the MD806 and MD809 groups, while there was no significant difference between the MD806 and MD809 groups. Given that the expression regulatory elements were consistent across groups and the enzyme activity region of GAA was not altered, the increase in total enzyme activity suggests that the constructed secretory GAA variant achieved some improvement in protein expression level and protein stability.

[0160] Example 4: Preparation and Detection of AAV Vectors

[0161] (1) Packaging of recombinant AAV virus

[0162] The Bac-to-AAV system was used to package MD110, MD806, MD809, and MD811 AAV viruses. Briefly, the process consisted of the following stages: preparation of Bacmid, culturing Sf9 cells, transfection preparation and identification of two baculoviruses (RepCap baculovirus and AAV expression vector baculovirus), amplification of the two baculoviruses, co-infection of Sf9 cells with the two baculoviruses, harvesting the Sf9 cell pellet, lysing cells to release the AAV virus, ultracentrifugation to purify the AAV virus, membrane desalting and concentrating the AAV virus, and sterile filtration. The purified AAV product was then packaged and obtained.

[0163] (2) Detection of titer of recombinant AAV virus

[0164] The AAV genomic titer was determined using TaqMan probe qPCR. Two primers and fluorescently labeled probe sequences were designed at the CAR promoter as follows:

[0165] qpcr-TaqMan-CA-F (SEQ ID NO. 38): TAACGCCAATAGGGACTTTCCA

[0166] qpcr-TaqMan-CA-R (SEQ ID NO. 39): CGGGCCATTTACCGTCATTG

[0167] Probe-TaqMan-CA(SEQ ID NO.40):

[0168] CAATGGGTGGAGTATTTACGGTAAACTGCCCACT

[0169] After extracting the genome from the AAV sample, Taqman qPCR was performed to determine the copy number of the CAR promoter in the extracted AAV genome, thereby determining the physical titer of each AAV product.

[0170] Example 5: AAV in vitro infection test

[0171] Huh-7 cells were seeded into 6-well plates. When cell confluence reached approximately 80%, cells were digested and counted. Based on the count, the required viral load was calculated at 50,000 viral particles per cell. The virus was mixed with fresh culture medium and added to the corresponding wells. Incubation was performed at 37°C. 6-8 hours post-infection, the virus-containing medium was replaced with fresh medium containing 1% serum. After 48 hours of continued culture, the cell culture supernatant was collected, and the cells were digested and collected. Cell lysates were prepared using repeated freeze-thaw cycles followed by centrifugation, and total cellular protein was extracted. The total protein concentration of cells infected with AAV products and uninfected blank cells was determined using the Pierce BCA Protein Aaasy Kit (ThermoFisher, USA). Detailed procedures were performed according to the kit instructions.

[0172] Following the same procedure as shown in Example 3, cell lysate extracts and supernatants were taken to detect GAA protease activity, and the total enzyme activity after transfection was calculated based on the total protein content and the total volume of the supernatant. Figure 4 The results showed that the AAV9-MD806, MD809, and MD811 groups were significantly higher than the control group and the AAV9-MD110 group. Among them, the AAV9-MD811 group was higher than the AAV9-MD806 and AAV9-MD809 groups, but there was no significant difference. This may be due to the poor expression efficiency of AAV9 in vitro.

[0173] Example 6 Wild-type C57 mouse experiment

[0174] Fifteen 8-week-old male wild-type C57 mice were randomly divided into 5 groups. One group served as the negative control, with each mouse receiving an intravenous injection of 200 μL PBS. The other four groups served as experimental groups, receiving one of four AAV products at a dose of 5E12 vg / kg. Mice were euthanized 4 weeks after administration for tissue collection. Hearts and livers with high AAV9 transduction levels were collected to evaluate intracellular GAA enzyme activity, and anticoagulated plasma was collected to evaluate the secretion levels of the products.

[0175] Tissue was homogenized in 10 volumes of PBS containing a protease inhibitor (PMSF, Solarbio), and then subjected to repeated freeze-thaw cycles followed by centrifugation to prepare tissue extracts. Blood was collected in anticoagulant tubes, and plasma was separated. Following the same procedure as in Example 3, the protein content in the tissue extracts was determined using the Pierce BCA Protein Aaasy Kit (ThermoFisher, USA); and the GAA enzyme activity in both tissue extracts and plasma was measured. The enzyme activities in both tissue and plasma were significantly higher in the treatment groups than in the control group. In the heart and liver, the enzyme activity of AAV9-MD110 was significantly higher than in other groups, and the AAV9-MD811 group was significantly higher than the AAV9-MD806 and AAV9-MD809 groups; in plasma, the GAA enzyme activity of AAV9-MD110 was significantly lower than in other treatment groups, with AAV9-MD811 showing the best activity, and no significant difference between the AAV9-MD806 and AAV9-MD809 groups (see Example 3). Figure 5 and Figure 6 This indicates that, compared to wild-type GAA which is mainly retained in tissue cells, secretory GAA variants, although reducing the amount of GAA remaining in tissue cells to some extent, can significantly increase the amount of expressed GAA secreted into the blood. Among them, AAV9-MD811 not only has the best secretion level, but also has a relatively small impact on enzyme activity in tissue cells.

[0176] Sequence information:

[0177] SEQ ID NO.1: GAA amino acid sequence

[0178]

[0179] SEQ ID NO.11: Natural GAA signal peptide sequence

[0180] MGVRHPPCSHRLLAVCALVSLATAALL

[0181] SEQ ID No. 2 and 12: A1AT signal peptide nucleic acid sequence and amino acid sequence. Nucleic acid sequence: ATGCCCTCCTCTGTGTCATGGGGCATCCTCCTGCTGGCTGGCTTGTGCTGCTTGGTCCCCGTGAGCTTGGCA

[0182] Amino acid sequence: MPSSVSWGILLLAGLCCLVPVSLASEQ ID No. 3 and 13: A2MG signal peptide nucleic acid sequence and amino acid sequence Nucleic acid sequence: ATGGGCAAGAACAAGCTGCTGCACCCCTCCCTGGTCCTGTTGTTGCTGGTGCTGCTGCCTACGGACGCT

[0183] Amino acid sequence: MGKNKLLHPSLVLLLLVLLPTDA SEQ ID No. 4 and 14: ALBU signal peptide nucleic acid sequence and amino acid sequence. Nucleic acid sequence: ATGAAGTGGGTCACCTTCATCTCCCTGCTGTTCCTGTTCTCCAGTGCATACAGCAGGGGAGTGTTCAGGCGG

[0184] Amino acid sequence: MKWVTFISLLFLFSSAYSRGVFRR SEQ ID No. 5 and 15: APOA1 signal peptide nucleic acid sequence and amino acid sequence. Nucleic acid sequence: ATGAAGGCTGCAGTGCTGACCCTGGCTGTGCTTTTCCTGACAGGGTCACAGGCT

[0185] Amino acid sequence: MKAAVLTLAVLFLTGSQA SEQ ID NO. 6 and 16: GIP signal peptide nucleic acid sequence and amino acid sequence Nucleic acid sequence: ATGGTGGCAACCAAAACCTTCGCCTTGCTGCTGCTGAGTCTGTTTTTGGCTGTGGGACTGGGA

[0186] Amino acid sequence: MVATKTFALLLLSLFLAVGLG SEQ ID NO. 7 and 17: SMS signal peptide nucleic acid sequence and amino acid sequence. Nucleic acid sequence: ATGCTGAGCTGTAGACTGCAGTGCGCGCTGGCTGCTCTGTCCATTGTGCTGGCTCTGGGAT GCGTGACAGGA

[0187] Amino acid sequence: MLSCRLQCALAALSIVLALGCVTG SEQ ID NO. 8 and 18: SP7 signal peptide nucleic acid sequence and amino acid sequence Nucleic acid sequence: ATGGCCTTCCTGTGGCTGCTGTCATGTTGGGCTCTGCTGGGAACAACATTCGGC

[0188] Amino acid sequence: MAFLWLLSCWALLGTTFG SEQ ID NO. 9 and 19: SS8 signal peptide nucleic acid sequence and amino acid sequence

[0189] Nucleic acid sequence: ATGTGGATGGTGGTGGTGCTGGTGTGCCTGCAGCTGCTGGAGGCA

[0190] Amino acid sequence: MWMVVVLVCLQLLEASEQ ID NO.10: CAR promoter sequence

[0191]

[0192] SEQ ID NO.20: Primer KZ-110sp-F1

[0193] GACGCGCTATGCGGC

[0194] SEQ ID NO.21: Primer KZ-110sp-R2

[0195] ATGGTCTGTAGCTTCCTGCA

[0196] SEQ ID NO.22: Primer KZ-A1ATsp-R1

[0197]

[0198] SEQ ID NO.23: Primer KZ-A1ATsp-F2

[0199]

[0200] SEQ ID NO.24: Primer KZ-A2MG-R1

[0201]

[0202] SEQ ID NO.25: Primer KZ-A2MG-F2

[0203]

[0204] SEQ ID NO.26: Primer KZ-ALBUsp-R1

[0205]

[0206] SEQ ID NO.27: Primer KZ-ALBUsp-F2

[0207]

[0208] SEQ ID NO.28: Primer KZ-APOA1sp-R1

[0209]

[0210] SEQ ID NO.29: Primer KZ-APOA1sp-F2

[0211]

[0212] SEQ ID NO.30: Primer KZ-GIPsp-R1

[0213]

[0214] SEQ ID NO.31: Primer KZ-GIPsp-F2

[0215]

[0216] SEQ ID NO.32: Primer KZ-SMS-nR1

[0217]

[0218] SEQ ID NO.33: Primer KZ-SMS-nF2

[0219]

[0220] SEQ ID NO.34: Primer KZ-sp7-nR1

[0221]

[0222] SEQ ID NO.35: Primer KZ-sp7-nF2

[0223]

[0224] SEQ ID NO.36: Primer KZ-SS8sp-R1

[0225]

[0226] SEQ ID NO.37: Primer KZ-SS8sp-F2

[0227]

[0228] SEQ ID NO.38: Primer qpcr-TaqMan-CA-F

[0229] TAACGCCAATAGGGACTTTCCA

[0230] SEQ ID NO.39: Primer qpcr-TaqMan-CA-R

[0231] CGGGCCATTTACCGTCATTG

[0232] SEQ ID NO.40: Probe-TaqMan-CA

[0233] CAATGGGTGGAGTATTTACGGTAAACTGCCCACT

[0234] SEQ ID NO.41: △35-GAA truncated form

[0235]

[0236] SEQ ID NO.42: △70-GAA truncated form

Claims

1. A secretory acidic α-glucosidase (GAA) polypeptide comprising or consisting of a truncated GAA polypeptide with a heterologous secretory signal peptide fused to its N-terminus, wherein the heterologous secretory signal peptide comprises or consists of an amino acid sequence selected from SEQ ID NOs:2-8, particularly the amino acid sequence of SEQ ID NO:2, 5, or 7, wherein the truncated GAA polypeptide is truncated by 35 to 70 consecutive amino acids, for example 35 or 70 consecutive amino acids, at the N-terminus relative to the full-length GAA.

2. The secretory GAA polypeptide of claim 1, wherein the truncated GAA polypeptide is truncated by 35 consecutive amino acids at the N-terminus relative to the full-length GAA.

3. The secretory GAA polypeptide according to any one of claims 1-2, wherein the full-length GAA polypeptide is a human full-length GAA polypeptide.

4. The secretory GAA polypeptide according to any one of claims 1-3, wherein the truncated GAA polypeptide comprises or consists of the amino acid sequence shown in SEQ ID NO:41 or SEQ ID NO:

42.

5. The secretory GAA polypeptide according to any one of claims 1-4, wherein it has or does not have a methionine at the N-terminus of the heterologous signal peptide.

6. A polynucleotide encoding the secretory GAA polypeptide of any one of claims 1-5.

7. The polynucleotide of claim 6, wherein the heterologous signal peptide is encoded by a nucleotide sequence selected from SEQ ID NOs:12-18, especially a nucleotide sequence of SEQ ID NO:12, 15 or 17.

8. An expression construct comprising the following elements functionally linked to each other in a transcriptional direction: - Promoter, - A polynucleotide encoding a secretory GAA polypeptide according to claim 6 or 7.

9. The expression construct according to claim 8, wherein the promoter is selected from constitutive promoters and tissue-specific promoters, particularly constitutive promoters selected from: CAG promoter, CAR promoter, PGK promoter, SV40 early promoter, human elongation factor 1α subunit (EF1α) promoter, cytomegalovirus (CMV) early gene promoter, chicken β-actin (CBA) promoter, β-glucuronidase (GUSB) promoter or ubiquitin C (UBC) promoter.

10. The expression construct according to any one of claims 8-9, wherein the promoter is the CAR promoter shown in SEQ ID NO:

10.

11. The expression construct according to any one of claims 8-10, comprising the following elements functionally linked to each other in the transcriptional direction: - Promoter, -Optional, Kozak sequence -A polynucleotide encoding secretory GAA, and - A transcription terminator, such as a polyA sequence selected from the late polyA sequence of SV40, the polyA sequence of rabbit β-globin, and the polyA sequence of bovine growth hormone.

12. A vector comprising the expression construct of any one of claims 8-11, wherein the vector is optionally a plasmid or a viral vector, such as a recombinant lentiviral vector, a recombinant AAV viral vector, or a baculovirus vector.

13. A recombinant adeno-associated virus (AAV) vector, wherein the recombinant AAV vector contains in its genome: a.5' and 3' AAV inverted terminal repeat (ITR) sequences, and b. An expression construct located between the 5' and 3' ITRs according to any one of claims 8-11.

14. The recombinant AAV viral vector of claim 13, wherein, The polynucleotide encoding the truncated GAA is a human codon-optimized sequence.

15. The recombinant AAV viral vector of claim 13 or 14, wherein the ITR is a wild-type AAV2 ITR sequence, or one of the ITRs is an AA2ΔITR sequence lacking a functional terminal unwinding site (trs) and optionally a D sequence.

16. The recombinant AAV virus vector of any one of claims 13-15, wherein the vector is an ssAAV vector or an scAAV vector.

17. The recombinant AAV viral vector of any one of claims 13-16, wherein the recombinant AAV vector comprises a capsid protein from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVPHP.B and AAVPHP.eB, especially serotype AAV9, or comprises a chimeric capsid, preferably, the recombinant AAV vector is an AAV2 / 9 vector.

18. A host cell comprising the polynucleotide of any one of claims 6-7 or the expression construct of any one of claims 8-11, or transformed with the vector of any one of claims 12 or 13-17.

19. The host cell of claim 18, wherein it is a hepatocyte or a muscle cell.

20. A pharmaceutical composition comprising a secretory GAA polypeptide of any one of claims 1-5, a polynucleotide of any one of claims 6-7, an expression construct of any one of claims 8-11, a vector of any one of claims 12 or 13-17 or a cell of claim 18, and optionally a pharmaceutically acceptable carrier.

21. Use of the secretory GAA polypeptide of any one of claims 1-5, the polynucleotide of any one of claims 6-7, the expression construct of any one of claims 8-11, the vector of any one of claims 12 or 13-17, or the cell of claim 18 in the preparation of a medicament, wherein the medicament is used for the prevention or treatment of acid α-glucosidase deficiency or glycogen storage disease.

22. The use according to claim 21, wherein the glycogen storage disease is selected from glycogen storage disease type II (GSD II, Pompe disease) or glycogen storage disease type III (GSD III).

Citation Information

Patent Citations

  • Recombinant adeno-associated viruses carrying designed SMN1 gene expression cassettes and application

    CN108795946A

  • Acid-alpha glucosidase variants and uses thereof

    CN110050063A

  • Gene therapy constructs, pharmaceutical compositions and methods for treating pompe disease

    CN115772520A

  • Improved constructs for expressing lysosomal polypeptides

    WO2004064750A2

  • Method of treating glycogen storage disease

    WO2010005565A2